New findings support the use of serum neurofilament light chain as a biomarker of MS outcomes

A new study of a large, heterogeneous cohort of MS patients has provided evidence for the potential usefulness of serum neurofilament light chain (sNfL) as a biomarker of disease burden in MS: elevated sNfL levels are associated with poor neurologic outcomes and with diabetes.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.